{{Short description|Chemical compound}} {{cs1 config|name-list-style=vanc|display-authors=6}} {{Drugbox | Verifiedfields = | Watchedfields = | verifiedrevid = | IUPAC_name = (2''S'')-1-[4-(3,4-Dichlorophenyl)piperidin-1-yl]-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol<ref name="KatoSaijo2012">{{cite journal | vauthors = Saijo T, Maeda J, Okauchi T, Maeda J, Morio Y, Kuwahara Y, Suzuki M, Goto N, Fukumura T, Suhara T, Higuchi M | title = Presynaptic selectivity of a ligand for serotonin 1A receptors revealed by in vivo PET assays of rat brain | journal = PLOS ONE | volume = 7 | issue = 8 | article-number = e42589 | year = 2012 | pmid = 22880045 | pmc = 3413639 | doi = 10.1371/journal.pone.0042589 | bibcode = 2012PLoSO...742589S | doi-access = free }}</ref> | image = MIN-117.svg | image_class = skin-invert-image | width = 250px
<!--Clinical data--> | tradename = | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_US = <!-- A / B / C / D / X --> | pregnancy_category = | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration =
<!--Pharmacokinetic data--> | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =
<!--Identifiers--> | CAS_number_Ref = | CAS_number = 310392-94-0 | CAS_supplemental = | ATC_prefix = | ATC_suffix = | PubChem = 9806065 | DrugBank_Ref = | DrugBank = | ChemSpiderID_Ref = | ChemSpiderID = 7981825 | UNII = QM05G7NM4H
<!--Chemical data--> | C= 25 | H=25 | Cl=2 | N=3 | O=1 | SMILES = CC1=NN=C(O1)C2=CC3=C(O2)C=CC=C3OC[C@H](CN4CCC(CC4)C5=CC(=C(C=C5)Cl)Cl)O | StdInChI_Ref = | StdInChI = 1S/C25H25Cl2N3O4/c1-15-28-29-25(33-15)24-12-19-22(3-2-4-23(19)34-24)32-14-18(31)13-30-9-7-16(8-10-30)17-5-6-20(26)21(27)11-17/h2-6,11-12,16,18,31H,7-10,13-14H2,1H3/t18-/m0/s1 | StdInChIKey_Ref = | StdInChIKey = XIYDIPLATGRHEC-SFHVURJKSA-N | synonyms = WF-516 }}
'''MIN-117''' (known formerly as '''WF-516''') is an investigational antidepressant which is under development by Minerva Neurosciences for the clinical treatment of major depressive disorder (MDD).<ref name="Minerva2015a">{{cite web | title = Minerva Neuroscience | url = http://minervaneurosciences.com/ | access-date = 2015-05-19}}</ref><ref name="Minerva2015b">{{cite press release | title = Minerva Neurosciences Reports First Quarter 2015 Financial Results and Other Key Business Updates | author = Minerva Neurosciences | publisher = GlobalNewswire | year = 2015 | url = http://globenewswire.com/news-release/2015/05/07/733476/10133133/en/Minerva-Neurosciences-Reports-First-Quarter-2015-Financial-Results-and-Other-Key-Business-Updates.html | access-date = 2015-05-19}}</ref><ref name="Minerva2015c">{{cite web|title=Investor Presentation March 2015 |author=Minerva Neurosciences |url=http://files.shareholder.com/downloads/AMDA-2MIFBM/0x0x813311/13B96B22-1D5F-470D-888B-8E1F47FE6AFA/Minerva_Investor_Presentation_-_March_2015.pdf |access-date=2015-05-19 |archive-url=https://web.archive.org/web/20150520033706/http://files.shareholder.com/downloads/AMDA-2MIFBM/0x0x813311/13B96B22-1D5F-470D-888B-8E1F47FE6AFA/Minerva_Investor_Presentation_-_March_2015.pdf |archive-date=2015-05-20 }}</ref> It is described as a 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptor antagonist and inhibitor of serotonin and dopamine reuptake,<ref name="Minerva2015c" /><ref name="Reuters2015">{{cite web | title = Company Profile for Minerva Neurosciences Inc. | publisher = Reuters | url = http://in.reuters.com/finance/stocks/companyProfile?symbol=NERV.O | archive-url = https://web.archive.org/web/20150520163323/http://in.reuters.com/finance/stocks/companyProfile?symbol=NERV.O | archive-date = 2015-05-20 | access-date = 2015-05-19}}</ref><ref name="SeekingAlpha2015">{{cite web | title = Some Nerves Surrounding Minerva Neurosciences IPO | first = Don | last = Dion | publisher = Seeking Alpha | year = 2014 | url = http://seekingalpha.com/article/2285733-some-nerves-surrounding-minerva-neurosciences-ipo | access-date = 2015-05-19}}</ref> and is also reported to possess affinity for the α<sub>1A</sub>- and α<sub>1B</sub>-adrenergic receptors.<ref name="Minerva2015c" /><ref name="SeekingAlpha2015" /> As of May 2015, MIN-117 is in phase II clinical trials for MDD.<ref name="Minerva2015b" /> In December 2019, Minerva announced that MIN-117 was no longer in clinical development for MDD after disappointing results in a phase IIb trial.<ref>{{Cite web|title=Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder|url=https://www.biospace.com/article/minerva-neurosciences-reports-topline-results-from-phase-2b-trial-of-min-117-in-major-depressive-disorder/|access-date=2020-07-28|website=BioSpace|language=en-US|archive-date=2020-07-29|archive-url=https://web.archive.org/web/20200729081705/https://www.biospace.com/article/minerva-neurosciences-reports-topline-results-from-phase-2b-trial-of-min-117-in-major-depressive-disorder/|url-status=dead}}</ref>
== See also == * List of investigational antidepressants
== References == {{Reflist|30em}}
== External links == * [http://www.minervaneurosciences.com/innovation-pipeline/min-117/ MIN-117 - Minerva Neurosciences] * [https://web.archive.org/web/20150520033706/http://files.shareholder.com/downloads/AMDA-2MIFBM/0x0x813311/13B96B22-1D5F-470D-888B-8E1F47FE6AFA/Minerva_Investor_Presentation_-_March_2015.pdf Investor Presentation March 2015 - Minerva Neurosciences] * [http://adisinsight.springer.com/drugs/800037483 MIN-117 - AdisInsight]
{{Adrenergic receptor modulators}} {{Monoamine reuptake inhibitors}} {{Serotonin receptor modulators}}
Category:4-Phenylpiperidines Category:5-HT1A antagonists Category:5-HT2A antagonists Category:Experimental antidepressants Category:Benzofuran ethers Category:Serotonin–dopamine reuptake inhibitors
{{nervous-system-drug-stub}}